CareDx (CDNA) Tops Q3 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CareDx Reports Third Quarter 2016 Financial Results
November 9, 2016 4:01 PM ESTBRISBANE, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the third quarter ended September 30, 2016.
Recent highlights:
Achieved total revenue for the third quarter of 2016 of $12.5M, up 74% year-over-year AlloMap® revenues were $8.6M in the quarter, with US tests volume up by 6% year-over-yearOlerup® revenues contributed $3.8M in the third quarter Launched Olerup... More